We’re moving! Datasets in the NIAGADS database are being transitioned to the DSS database, more info coming soon.
The NIA ADC cohort included subjects ascertained and evaluated by the clinical and neuropathology cores of the 39 past and present NIA-funded Alzheimer's Disease Centers (ADC). Data collection is coordinated by the National Alzheimer’s Coordinating Center (NACC). NACC coordinates collection of phenotype data from the ADCs, cleans all data, coordinates implementation of definitions of AD cases and controls, and coordinates collection of samples. Biological specimens are collected, stored, and distributed by the National Cell Repository for Alzheimer’s Disease (NCRAD).
This GWAS dataset, ADC7, is the seventh set of ADC genotyped subjects used by the Alzheimer's Disease Genetics Consortium (ADGC) to identify genes associated with an increased risk of developing late-onset Alzheimer’s disease (LOAD). The genomic dataset was first published in Kunkle et al. For deeper phenotypes, contact NACC.
The ADC7 sample set was genotyped using the Infinium HumanOmniExpressExome BeadChip, which captures genotype data on 964,193 genomic SNPs. This includes a selected subset of 273,246 functional exonic variants that heavily overlap with the variants genotyped on Illumina's previous exome chip array. As many exome chip association and genome-wide association analyses are performed separately, we have extracted the exonic variants into separate PLINK-formatted files from the remaining ~690,000 variants in order to facilitate ease of analysis, and simplifying combining files with overlapping marker sets (samples genotyped only on GWAS arrays or only on exome chip arrays). Quality control was performed separately for the genomic and exonic datasets. The exome chip data was first reported in the Sims et al. publication.
Detailed information about the dataset is provided in the following document: NG00071_ADC7_README.txt
The NIA Genetics of Alzheimer's Disease Data Storage Site (NIAGADS) is supported by a collaborative agreement from the National Institute on Aging, U01AG041689.
NG00022, NG00023, NG00024, NG00068, NG00069, NG00070, NG00071: The NACC database is funded by NIA/NIH Grant U01 AG016976. NACC data are contributed by the NIA-funded ADCs: P30 AG019610 (PI Eric Reiman, MD), P30 AG013846 (PI Neil Kowall, MD), P50 AG008702 (PI Scott Small, MD), P50 AG025688 (PI Allan Levey, MD, PhD), P50 AG047266 (PI Todd Golde, MD, PhD), P30 AG010133 (PI Andrew Saykin, PsyD), P50 AG005146 (PI Marilyn Albert, PhD), P50 AG005134 (PI Bradley Hyman, MD, PhD), P50 AG016574 (PI Ronald Petersen, MD, PhD), P50 AG005138 (PI Mary Sano, PhD), P30 AG008051 (PI Steven Ferris, PhD), P30 AG013854 (PI M. Marsel Mesulam, MD), P30 AG008017 (PI Jeffrey Kaye, MD), P30 AG010161 (PI David Bennett, MD), P50 AG047366 (PI Victor Henderson, MD, MS), P30 AG010129 (PI Charles DeCarli, MD), P50 AG016573 (PI Frank LaFerla, PhD), P50 AG016570 (PI Marie-Francoise Chesselet, MD, PhD), P50 AG005131 (PI Douglas Galasko, MD), P50 AG023501 (PI Bruce Miller, MD), P30 AG035982 (PI Russell Swerdlow, MD) , P30 AG028383 (PI Linda Van Eldik, PhD), P30 AG010124 (PI John Trojanowski, MD, PhD), P50 AG005133 (PI Oscar Lopez, MD), P50 AG005142 (PI Helena Chui, MD), P30 AG012300 (PI Roger Rosenberg, MD), P50 AG005136 (PI Thomas Montine, MD, PhD), P50 AG033514 (PI Sanjay Asthana, MD, FRCP), P50 AG005681 (PI John Morris, MD), and P50 AG047270 (PI Stephen Strittmatter, MD, PhD).
Samples from the National Cell Repository for Alzheimer’s Disease (NCRAD), which receives government support under a cooperative agreement grant (U24 AG21886) awarded by the National Institute on Aging (NIA), were used in this study. We thank contributors who collected samples used in this study, as well as patients and their families, whose help and participation made this work possible.
The Alzheimer's Disease Genetics Consortium supported the collection of samples used in this study through National Institute on Aging (NIA) grants U01AG032984 and RC2AG036528.